35results about How to "Advantages and Significant Advancements" patented technology

The invention discloses an atorvastatin calcium tablet and a preparation method thereof. The tablet contains atorvastatin calcium, polacrilin potassium IRP-88, carbomer 971P, acrylic resin IV, and ethyl cellulose and other pharmaceutically acceptable excipients. The present invention successfully solves the stability problem during the preparation and storage of atorvastatin calcium, and prepares the solid dispersion of atorvastatin calcium by using solvent deposition technology, which greatly improves the solubility of the drug; at the same time, through semi-permeable membrane coating, Side effects such as upset stomach are reduced.

The invention discloses a crotamiton-containing external preparation and a preparation process thereof. The external preparation is prepared from the following components in parts by weight: 100 parts of crotamiton, 200-400 parts of diethylene glycol monoethyl ether, 100-200 parts of decanoyl / octanoyl-glycerides and 400-600 parts of poloxamers. The preparation process particularly comprises the following steps: dissolving the crotamiton into the diethylene glycol monoethyl ether; then adding the decanoyl / octanoyl-glycerides and the poloxamers; and stirring for dissolution. The preparation process disclosed by the invention is simple, fundamentally avoids the problem that a medicament is separated from a matrix and is favorable to long-term storage and transportation.

The invention relates to a mosapride citrate tablet and a preparation method thereof, and belongs to the technical field of medical preparations which are applied to medical use and contain organic active ingredients. With mosapride citrate as a raw material and lactose, starch and hydroxypropyl methylcellulose as adjuvant materials, and assisted by aids, the mosapride citrate tablet is prepared by conducting wet-process granulation and tabletting. The mosapride citrate tablet provided by the invention, when applied to the preparation of gastric motor drugs, has the characteristics of being rapid in dissolution, good in stability, simple in preparation process, easy for industrial mass production and the like.

The invention discloses a felodipine sustained release tablet and a preparation technology thereof and belongs to the field of chemical drug preparations. The felodipine sustained release tablet comprises a felodipine solid dispersion agent, a filling agent, a disintegrating agent and a lubricating agent. The method comprises the following steps: mixing and suspending felodipine, carbomer resin and sodium alginate in absolute ethyl alcohol, drying and removing ethyl alcohol, thereby acquiring the felodipine solid dispersion agent; uniformly mixing with the filling agent and the disintegratingagent, by taking 60% ethyl alcohol as an adhesive, pelletizing and drying at 45 DEG C, thereby acquiring medicated particles; filtering the medicated particles with a 18-mesh sieve, uniformly mixing with a prescription amount of lubricating agent and preforming. The invention successfully solves the problem of felodipine sustained release; the drugs can be completely released; the effective bloodconcentration can be long-term maintained; the bioavailability is high; the preparation process is simple and is suitable for industrial production.

The invention discloses an eluxadoline enteric coated tablet and a preparation method thereof. The preparation method includes: mixing eluxadoline with a solubilizer evenly, then dissolving the mixture in a 95% ethanol solution, mixing the substances evenly, then adding an appropriate amount of lecithin, conducting drying at 50DEG C for 45min to obtain dry particles, performing sieving by a 80-mesh sieve, then mixing the product with a filling agent and a disintegrating agent evenly, adding a lubricant tablet, and finally carrying out isolating coating and enteric coating. The eluxadoline enteric coated tablet provided by the invention does not contain basic ingredients, reduces stomach discomfort and other side effects, glyceryl monostearate is added in the enteric coating to significantly improve the dissolution degree of eluxadoline and its stability in gastric juice. Dissolution experiments find that the eluxadoline dissolution degree increases significantly and no burst release phenomenon occurs, the 6h dissolution degree is above 99%, acceleration tests find that the eluxadoline enteric coated tablet has good stability during preparation and storage, the preparation process is simple, has no need for complex preparation equipment, and is easy to realize industrial mass production.